Pasithea Therapeutics' Conference Presentation Update
Pasithea Therapeutics Corp., a clinical-stage biotechnology firm focused on innovative solutions for treatment, has made an important update regarding its presentation at an upcoming global investment conference. The company is set to showcase its lead drug candidate, PAS-004, during the H.C. Wainwright 27th Annual Global Investment Conference happening in New York City.
New Date and Time for Presentation
The strategic change affects the timing of the management's live presentation. It is now scheduled for Monday, September 8, at 5:00 PM Eastern Time. This decision highlights Pasithea's commitment to transparently share their advancements in developing new treatments.
Live Company Presentation
Dr. Tiago Reis Marques, the CEO of Pasithea, will personally deliver the presentation. Attendees can look forward to deep insights into the company's clinical trials, focusing on the drug PAS-004. The management team will also be available for one-on-one meetings during the event, fostering engagement with potential investors and stakeholders.
Conference Presentation Details
The critical details are as follows:
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8, 2025
Time: 5:00 PM ET
Location: Lotte New York Palace Hotel
About Pasithea Therapeutics Corp.
Pasithea is engaged in pioneering work in biotechnology, focusing specifically on the treatment of disorders associated with the RAS pathway. The company's primary focus is the advancement of PAS-004, a next-generation macrocyclic MEK inhibitor aimed at treating RASopathies and MAPK pathway-driven tumors. This innovative approach could offer hope to patients suffering from conditions currently lacking effective therapies.
Clinical Trials Overview
As part of its dedication to transformation within the medical landscape, Pasithea is conducting rigorous clinical trials. Currently, PAS-004 is being tested in various phases, including a Phase 1 trial examining safety and efficacy metrics in advanced cancer patients, and a Phase 1/1b trial focused on individuals with neurofibromatosis type 1 associated plexiform neurofibromas. Such clinical studies play a crucial role in ensuring the safety and therapeutic potential of their drug candidates is thoroughly understood.
Company Engagement and Communication
Pasithea emphasizes its commitment to keeping its investors and the public informed about its progress. Regular updates not only ensure transparency but also build trust within the biopharmaceutical community. The anticipated presentation at the H.C. Wainwright Conference presents a valuable opportunity for direct communication with interested parties seeking to learn more about Pasithea's innovative solutions.
Contact Information for Inquiries
For any inquiries regarding Pasithea Therapeutics, especially ahead of the upcoming conference, stakeholders are encouraged to reach out to Patrick Gaynes, who is responsible for corporate communications. He can be contacted directly at pgaynes@pasithea.com.
Frequently Asked Questions
What is the focus of Pasithea Therapeutics?
Pasithea Therapeutics focuses on developing treatments for RASopathies and MAPK pathway-driven tumors through innovative therapies like PAS-004.
When and where is the presentation taking place?
The presentation is scheduled for September 8, 2025, at the H.C. Wainwright 27th Annual Global Investment Conference held at the Lotte New York Palace Hotel.
Who will be presenting for Pasithea?
Dr. Tiago Reis Marques, the CEO of Pasithea, will deliver the presentation on their innovative drug PAS-004 and its future implications.
How can investors engage with Pasithea?
Investors can engage through one-on-one meetings that will be offered during the conference, allowing direct interaction with management.
What is the mechanism of PAS-004?
PAS-004 is designed to act as a macrocyclic MEK inhibitor, targeting specific pathways associated with a range of cancers and related conditions.
